Decoration of pH-sensitive copolymer micelles with tumor-specific peptide for enhanced cellular uptake of doxorubicin

被引:15
作者
Chen, Qing [1 ]
Long, Miaomiao [2 ]
Qiu, Lipeng [3 ]
Zhu, Mengqin [3 ]
Li, Zhen [1 ]
Qiao, Mingxi [1 ]
Hu, Haiyang [1 ]
Zhao, Xiuli [1 ]
Chen, Dawei [1 ]
机构
[1] Shenyang Pharmaceut Univ, Sch Pharm, Dept Pharmaceut, 103 Wenhua Rd, Shenyang 110016, Peoples R China
[2] Nanjing Chia Tai Tianqing Pharmaceut Grp Co Ltd, Dept Res & Dev, Nanjing, Jiangsu, Peoples R China
[3] Jiangnan Univ, Sch Pharmaceut Sci, Dept Pharmaceut, 1800 Lihu Ave, Wuxi 214122, Peoples R China
基金
中国国家自然科学基金;
关键词
Her2; peptide; hyaluronic acid; poly(L-histidine); targeted delivery; antitumor efficacy; TARGETED INTRACELLULAR DELIVERY; SELF-ASSEMBLED NANOPARTICLES; SERUM-ALBUMIN NANOPARTICLES; HYALURONIC-ACID; CANCER-THERAPY; BREAST-CANCER; IN-VITRO; RECEPTOR; NANOCARRIERS; TRASTUZUMAB;
D O I
10.2147/IJN.S111950
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
To improve the targeting efficacy of hyaluronic acid (HA)-based micelles, pH-sensitive mixed micelles based on HA-g-poly(L-histidine) (PHis) and d-alpha-tocopheryl poly-ethylene glycol 2000 copolymers were prepared and decorated with human epidermal growth factor receptor 2 (Her2) peptide, a tumor cell-specific peptide ligand, on their surface. The doxorubicin-loaded micelles (HA-PHis/peptide-d-alpha-tocopheryl polyethylene glycol 2000 mixed micelles [PHTM]) were characterized to have a unimodal size distribution and pH-dependent drug release pattern. In vitro tumor targeting studies demonstrated that PHTM exhibited the pronounced cytotoxicity and efficient internalization in MDA-MB-231 cells overexpressing CD44 and Her2 receptors. In vivo investigation into micelles in MDA-MB-231 tumor-bearing mice confirmed that PTHM could reach the tumor site more effectively and exert excellent tumor killing activity. In general, Her2 peptide decoration can enhance the selective cytotoxicity and antitumor activity of HA-based micelles.
引用
收藏
页码:5415 / 526
页数:12
相关论文
共 48 条
[1]   Internalization of the hyaluronan receptor CD44 by chondrocytes [J].
Aguiar, DJ ;
Knudson, W ;
Knudson, CB .
EXPERIMENTAL CELL RESEARCH, 1999, 252 (02) :292-302
[2]   Expression of LYVE-1 in sinusoidal endothelium is reduced in chronically inflamed human livers [J].
Arimoto, Junko ;
Ikura, Yoshihiro ;
Suekane, Takehisa ;
Nakagawa, Masashi ;
Kitabayashi, Chizuko ;
Iwasa, Yoko ;
Sugioka, Kenichi ;
Naruko, Takahiko ;
Arakawa, Tetsuo ;
Ueda, Makiko .
JOURNAL OF GASTROENTEROLOGY, 2010, 45 (03) :317-325
[3]   New therapies in HER2-positive breast cancer: A major step towards a cure of the disease? [J].
Awada, Ahmad ;
Bozovic-Spasojevic, Ivana ;
Chow, Louis .
CANCER TREATMENT REVIEWS, 2012, 38 (05) :494-504
[4]   Clinical trials of Herceptin® (trastuzumab) [J].
Baselga, J .
EUROPEAN JOURNAL OF CANCER, 2001, 37 :S18-S24
[5]   Disabling ErbB receptors with rationally designed exocyclic mimetics of antibodies: Structure-function analysis [J].
Berezov, A ;
Zhang, HT ;
Greene, MI ;
Murali, R .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (16) :2565-2574
[6]   Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology [J].
Bertrand, Nicolas ;
Wu, Jun ;
Xu, Xiaoyang ;
Kamaly, Nazila ;
Farokhzad, Omid C. .
ADVANCED DRUG DELIVERY REVIEWS, 2014, 66 :2-25
[7]   Engineering novel binding proteins from nonimmunoglobulin domains [J].
Binz, HK ;
Amstutz, P ;
Plückthun, A .
NATURE BIOTECHNOLOGY, 2005, 23 (10) :1257-1268
[8]   Nanopreparations for organelle-specific delivery in cancer [J].
Biswas, Swati ;
Torchilin, Vladimir P. .
ADVANCED DRUG DELIVERY REVIEWS, 2014, 66 :26-41
[9]   Beyond natural antibodies: the power of in vitro display technologies [J].
Bradbury, Andrew R. M. ;
Sidhu, Sachdev ;
Duebel, Stefan ;
McCafferty, John .
NATURE BIOTECHNOLOGY, 2011, 29 (03) :245-254
[10]   Active targeting schemes for nanoparticle systems in cancer therapeutics [J].
Byrne, James D. ;
Betancourt, Tania ;
Brannon-Peppas, Lisa .
ADVANCED DRUG DELIVERY REVIEWS, 2008, 60 (15) :1615-1626